BLOO7 schreef op 13 juni 2019 15:39:
But new Gilead Sciences CEO Daniel O'Day said on his company's Q1 conference call that he wants to "accelerate some of the plans around filgotinib." Gilead plans to talk with the FDA. It seems possible that the big biotech could file for U.S. approval of filgotinib sooner than anticipated. [u]That would be great news for Galapagos.
www.fool.com/investing/2019/05/19/bet...Als het hem mocht lukken, dan weet ik niet of dit voor Galapagos goed nieuws zou betekenen. Het muurtje (de koers) is nog niet hoog genoeg.